8 news items
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
NVCR
3 Jun 24
of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
NVCR
2 May 24
of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products
Novocure Reports First Quarter 2024 Financial Results
NVCR
2 May 24
of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
NVCR
24 Apr 24
and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
NVCR
5 Apr 24
and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment
ymw5u0xg5ua
NVCR
ZLAB
27 Mar 24
))) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering
isq3tg1z wpa9m1t4mxce0z468hi4movlfs8
NVCR
27 Mar 24
company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative
ldn1qwc
NVCR
11 Mar 24
Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields
- Prev
- 1
- Next